Search

Background: Pregnant patients are potentially vulnerable to COVID-19., Objectives: To clarify the clinical features of COVID-19 and analyze maternal/fetal morbidity and mortality and the obstetric and neonatal outcomes of pregnant patients., Search Strategy: Embase, PubMed, Web of Science, CINAHAL, LILACS, Google Scholar, and Scopus., Selection Criteria: Articles published from December 2019 to February 2021., Data Collection and Analysis: The reviewers extracted relevant data from the full-text. Data synthesis was performed using the R-4.1.0 Project for Statistical Computing for Windows. The meta-analysis of the included studies was carried out using the random-effects model (DerSimonian and Laird). Heterogeneity was measured using I 2 analysis., Results: A total of 70 studies included 10 047 pregnant women with COVID-19, of whom 71.6% were in their third trimester. The most common symptoms were fever, cough, chest pain, dyspnea, and fatigue. Most newborns were delivered preterm (24%, 95% confidence interval [CI] 0.17-0.34, I 2  = 93%) and via cesarean delivery (42%, 95% CI 0.38-0.47, I 2  = 92%). There were 108 maternal mortalities (2%, 95% CI 0.01-0.03, I 2  = 54%) and 50 abortions (5%, 95% CI 0.03-0.09, I 2  = 73%). The neonatal outcomes included fetal distress (11%, 95% CI 0.06-0.19, I 2  = 91%), birth weight (15%, 95% CI 0.10-0.21, I 2  = 76%), APGAR <7 (19%, 95% CI 0.12-0.28, I 2  = 43%), admission to the neonatal intensive care unit (28%, 95% CI 0.17-0.43, I 2  = 90%), and fetal mortality (2%, 95% CI 0.01-0.03, I 2  = 46%)., Conclusion:  There was no evidence of severe acute respiratory syndrome coronavirus-2 in the placenta, breast milk, umbilical cord, and amniotic fluid of pregnant patients. PROSPERO registration number: CRD42020181519., (© 2021 International Federation of Gynecology and Obstetrics.)

Background: Although much has been studied about the SARS-Cov-2 virus, its effects, and the effectiveness of possible treatments, little is known about its interaction with other infectious diseases., Objective: The aim is to study its clinical features and morbidity, and mortality outcomes of COVID-19 patients with HIV/AIDS coinfection., Data Sources: MEDLINE, Web of Science, Embase, CINAHL, LILACS, Scopus, ClinicalTrials.gov, and Cochrane., Study Eligibility Criteria: Atudies in any language, published after 2019, were describing COVID-19 patients with HIV/AIDS., Study Appraisal: JBI Levels of Evidence, Joanna Briggs Institute., Synthesis Methods: As shown in the PRISMA flow diagram, two authors separately screened the search results from the obtained titles and abstracts., Results: Chest CT was observed in patients with pneumonia by SARS-CoV-2 with findings of multiple ground-glass opacities (GGO) in the lungs, there is a need for supplemental oxygenation. One patient developed encephalopathy and complicated tonic-clonic seizures; four patients were transplanted (two, liver; two, kidneys), one patient developed severe SARS-CoV-2 pneumonia and 30 patients died (mortality rate, 11%)., Conclusion: HIV did not show any relevance directly with the occurrence of COVID-19. Some studies suggest that HIV-1 infection through induction levels of IFN-I, may to some extent, stop the apparent SARS-CoV-2 infection, thus leading to undetectable RNA. Moreover, some authors suggest retroviral therapy routinely used to control HIV infection could be used to prevent COVID-19 infection.